Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...

Johnson & Johnson has reported new long‑term results from the QUASAR long‑term extension study, showing that Tremfya (guselkumab) sustained clinical, endoscopic and histologic outcomes through week ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Crohn’s and UC affect the GI tract differently. Crohn’s impacts the whole tract, while UC is limited to the colon. Learn the ...

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Walking is a simple, lower-intensity option that may help reduce stress, which can benefit people with UC. “Lower-impact and ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...